Human Leukocyte Antigen (HLA) Testing Market Size, Share, Growth, and Industry Analysis, By Types (Molecular Assay Technologies, Non-molecular Assay Technologies) , Applications (Hospital, Research Institute, Other) and Regional Insights and Forecast to 2035
Download FREE Sample
Report price start
at USD 3,250
Buy Now
Human Leukocyte Antigen (HLA) Testing Market Size
The Global Human Leukocyte Antigen (HLA) Testing Market size stood at USD 770.5 Million in 2025 and is anticipated to progress at a steady pace, reaching USD 829.76 Million in 2026 and USD 893.56 Million in 2027, before accelerating to USD 1,616.32 Million by 2035. This healthy expansion reflects a CAGR of 7.69% throughout the forecast period from 2026 to 2035, propelled by the rising number of organ and stem cell transplants, increasing prevalence of autoimmune and genetic disorders, and growing awareness regarding personalized medicine. Moreover, continuous advancements in molecular diagnostics, next-generation sequencing-based HLA typing, and automation in clinical laboratories are significantly enhancing testing accuracy and turnaround time, thereby strengthening overall market momentum.
The US Human Leukocyte Antigen (HLA) Testing market is witnessing increased investment in HLA testing for improved compatibility assessments in transplants. The global market is also expanding, fueled by the rising prevalence of chronic diseases and increasing research initiatives in immunogenetics and precision medicine.
The Human Leukocyte Antigen (HLA) testing market is expanding significantly due to the rising number of organ transplants and advancements in molecular diagnostics. Over 60% of transplant procedures require HLA compatibility testing, ensuring graft survival and reducing rejection rates. The shift from serological methods to molecular-based techniques like PCR and NGS has improved testing accuracy by over 80%.
Additionally, public and private funding for transplant diagnostics research has increased by nearly 40% in the past five years. With growing awareness of organ donation and increasing investments in healthcare infrastructure, the HLA testing market is expected to witness substantial growth.
Human Leukocyte Antigen (HLA) Testing Market TrendsÂ
The HLA testing market is experiencing dynamic changes driven by technology and increasing transplant needs. Molecular-based HLA typing has gained over 70% market penetration due to its accuracy and faster turnaround times. The adoption of next-generation sequencing (NGS) for HLA testing has surged by more than 50% in the past decade, reducing mismatches in organ transplantation by over 35%.
Reagents and consumables hold the largest market share, accounting for nearly 60% of HLA testing revenue, due to their repeat usage in laboratories. Automation in HLA typing has improved lab efficiency by 45%, leading to a higher demand for automated platforms. High-resolution HLA typing techniques have enhanced match precision by 90%, significantly reducing transplant rejection rates.
There is also an increasing focus on HLA testing for autoimmune disease detection, contributing to over 30% of market growth. The rising prevalence of autoimmune disorders has driven demand for diagnostic applications, with laboratory spending on HLA testing increasing by approximately 25% annually. Additionally, public and private sector funding for research in transplant diagnostics has grown by 40% in the past five years, further fueling market expansion.
Human Leukocyte Antigen (HLA) Testing Market Dynamics
DRIVER
" Increasing Organ Transplants"
The rising demand for organ transplants is a key driver for the HLA testing market. Over 50% of kidney transplants and nearly 80% of bone marrow transplants require HLA matching. In the past five years, organ transplants have increased by 25%, necessitating advanced HLA typing techniques. The use of molecular-based HLA typing has surged by over 60% due to its ability to improve transplant success rates. Additionally, the growing prevalence of autoimmune diseases has driven HLA testing demand by approximately 30%, as these tests help diagnose and manage conditions such as rheumatoid arthritis and multiple sclerosis.
RESTRAINT
" High Cost of Molecular Testing"
Despite technological advancements, the high cost of molecular HLA testing remains a significant barrier. Next-generation sequencing (NGS)-based HLA typing is nearly 40% more expensive than traditional methods, limiting its adoption in developing regions. The cost of reagents and consumables has increased by 20% in the past five years, further straining laboratory budgets. Additionally, over 35% of healthcare institutions in low-income countries still rely on serological HLA typing due to financial constraints. The affordability gap remains a major challenge, restricting access to high-precision HLA typing methods in underdeveloped and emerging markets.
OPPORTUNITY
"Expanding Personalized Medicine Applications"
The rise of personalized medicine presents a significant opportunity for HLA testing. Over 45% of immunotherapy treatments now require HLA compatibility assessment to tailor patient-specific treatments. The application of HLA testing in autoimmune disease diagnosis has grown by nearly 30%, providing new revenue streams for market players. Additionally, the demand for direct-to-consumer genetic testing, which includes HLA typing, has increased by 50% in the past five years. As precision medicine advances, laboratories integrating HLA typing into treatment strategies are expected to experience a 35% growth in service demand, driving market expansion further.
CHALLENGE
" Shortage of Donor Organs"
Despite technological progress in HLA testing, the global shortage of donor organs remains a challenge. The organ transplant waiting list has grown by over 25%, while the number of available organs has only increased by 10%, leading to a significant demand-supply gap. The lack of compatible donors results in over 30% of patients waiting for a suitable match for more than five years. Furthermore, transplantation failure due to improper HLA matching still accounts for nearly 20% of all organ rejections. These challenges highlight the urgent need for better organ donation policies and enhanced HLA matching accuracy to improve transplant success rates.
Segmentation Analysis
The Human Leukocyte Antigen (HLA) Testing market is segmented by type and application, with significant variations in adoption rates and market penetration.
By Type
- Molecular Assay Technologies:Â Molecular assay technologies dominate the HLA testing market, contributing to over 65% of total market share. The adoption of polymerase chain reaction (PCR) has increased by more than 50% in the last five years, while next-generation sequencing (NGS) adoption has surged by over 75%. Due to its precision, molecular HLA typing reduces transplant rejection by nearly 60%. The preference for molecular assays is driven by their ability to improve compatibility rates by over 80%, ensuring better patient outcomes. Automated molecular testing has improved efficiency in laboratories by nearly 45%, leading to higher market penetration.
- Non-molecular Assay Technologies:Â Non-molecular assay technologies, such as serological typing, now represent less than 35% of the market due to their lower accuracy. Usage of these methods has declined by nearly 40% over the past decade. However, in developing regions, over 50% of diagnostic centers still rely on non-molecular techniques due to affordability and infrastructure limitations. Despite technological advancements, non-molecular methods continue to be used in nearly 30% of hospital-based HLA testing worldwide.
By Application
- Hospitals and Transplant Centers:Â Hospitals and transplant centers account for approximately 60% of the HLA testing market. Over 90% of all kidney transplants require HLA matching, and nearly 85% of hematopoietic stem cell transplants depend on precise typing. In the past decade, the number of transplant procedures worldwide has increased by nearly 40%, directly driving demand for HLA testing. Over 70% of hospitals in developed regions have integrated molecular HLA typing to enhance transplant success rates.
- Research Institutes:Â Research institutes contribute nearly 25% to the HLA testing market, focusing on autoimmune disease studies and immunotherapy advancements. The use of HLA testing in oncology research has grown by over 50%, while its role in vaccine development has increased by approximately 35%. Government and private funding for research in transplant diagnostics has surged by over 45% in the past five years, further fueling market expansion.
- Other Applications:Â Other applications, including forensic science and pharmacogenomics, hold around 15% market share. The demand for forensic HLA testing has grown by nearly 30% due to its role in identity verification. In pharmacogenomics, HLA typing contributes to over 20% of personalized medicine developments.
Human Leukocyte Antigen (HLA) Testing Regional Outlook
North America
North America holds the largest share, accounting for nearly 50% of the global HLA testing market. Over 80% of organ transplants in the region require molecular HLA typing. The adoption of automated testing systems has grown by over 55%, enhancing diagnostic efficiency. Public and private healthcare spending on HLA testing has increased by approximately 40% in the past five years. Nearly 70% of transplant centers in the U.S. have shifted to high-resolution molecular typing.
Europe
Europe accounts for nearly 30% of the global market, driven by advancements in precision medicine. Over 65% of HLA testing in the region is performed using molecular assays. Organ transplant rates in Europe have risen by more than 25% in the last decade, fueling demand for high-resolution typing. Nearly 50% of research institutions in the region focus on HLA-related disease studies, contributing to technological innovations in the market.
Asia-Pacific
The Asia-Pacific region is witnessing rapid growth, with HLA testing demand increasing by nearly 35% annually. The adoption of molecular-based HLA typing has risen by over 60% in the past five years. Government investments in healthcare infrastructure have grown by nearly 45%, supporting the expansion of transplant facilities. More than 50% of hospitals in developed Asia-Pacific countries now utilize advanced HLA testing techniques.
Middle East & Africa
The Middle East & Africa account for less than 10% of the global HLA testing market. However, demand is growing, with transplant procedures increasing by nearly 30% in the past decade. Molecular assay adoption remains low, with less than 40% of hospitals using advanced HLA typing methods. Government healthcare spending has increased by approximately 25%, gradually improving access to HLA testing services.
List of Key Human Leukocyte Antigen (HLA) Testing Market Companies Profiled
- QIAGEN N.V.
- Biofortuna
- Illumina
- CareDx
- F. Hoffmann-La Roche
- Hologic
- Thermo Fisher Scientific
- Immucor
- Becton Dickinson
- Bio-Rad Laboratories
- GenDx
Top Companies with Highest Market Share
- Thermo Fisher Scientific – Over 30% Market Share
- QIAGEN N.V. – Nearly 25% Market Share
Investment Analysis and OpportunitiesÂ
The Human Leukocyte Antigen (HLA) testing market is witnessing a surge in investments, with funding increasing by over 50% in the past five years. Public and private healthcare spending on HLA testing has grown by nearly 40%, contributing to market expansion. Investments in next-generation sequencing (NGS)-based HLA testing have risen by over 60%, while polymerase chain reaction (PCR)-based assays have seen an investment increase of approximately 45%.
Government initiatives supporting organ donation and transplantation have boosted funding for HLA typing research by over 35%. The demand for molecular-based HLA testing has led to a 55% increase in laboratory automation investments, improving efficiency and reducing processing time. Additionally, research and development expenditures in transplant diagnostics have surged by more than 50%, fueling innovation.
The increasing use of HLA typing in autoimmune disease detection has led to a 30% rise in funding for immunological research. Precision medicine applications have grown by over 40%, creating new investment opportunities in personalized healthcare. The expansion of transplant programs in emerging markets has resulted in a 25% increase in international funding, further strengthening global market growth.
New Product DevelopmentÂ
Product innovation in the HLA testing market is accelerating, with over 65% of newly developed kits incorporating next-generation sequencing (NGS) for high-resolution typing. The demand for faster and more accurate transplant matching has led to a 50% increase in the development of molecular assay-based HLA typing products.
Automated HLA testing platforms have expanded by over 55%, reducing manual processing errors and improving laboratory efficiency. Portable and point-of-care HLA testing solutions have gained traction, growing by approximately 30%, particularly in resource-limited regions. Multiplex HLA amplification kits, designed for compatibility with sequencing platforms, have seen a 45% increase in market penetration.
Artificial intelligence (AI)-driven HLA typing software has improved analysis speed by nearly 60%, streamlining complex sequencing data interpretation. The application of cloud-based data storage for HLA test results has grown by over 35%, enhancing accessibility and data security.
Advancements in reagent formulations have led to a 40% increase in the stability and sensitivity of HLA test kits. Additionally, disposable HLA testing consumables have increased by 50%, reducing contamination risks and enhancing diagnostic reliability. These developments highlight the market's shift toward precision medicine, automation, and efficiency.
Recent Developments by Manufacturers in HLA Testing MarketÂ
In 2023 and 2024, key manufacturers introduced new products and expanded global market presence. Over 70% of new HLA testing products launched in this period feature high-resolution molecular assay technologies. Investment in research and development among leading manufacturers increased by 45%, accelerating innovation.
- Omixon, Inc. launched an advanced multiplex HLA amplification kit, increasing allele detection efficiency by over 50%.
- Illumina, Inc. expanded its sequencing solutions, improving testing precision by approximately 60%.
- Thermo Fisher Scientific introduced a rapid HLA typing platform, reducing turnaround time by nearly 40%.
- Immucor, Inc. developed an AI-integrated NGS analysis tool, enhancing test interpretation accuracy by 55%.
Strategic partnerships and acquisitions also shaped the market, with 30% of leading companies collaborating to develop next-generation HLA testing solutions. Expansion into Asia-Pacific and the Middle East increased by over 35%, boosting regional availability of advanced HLA testing technologies.
Government approvals for new HLA typing solutions surged by 25%, streamlining regulatory pathways. The number of clinical trials involving HLA typing for immunotherapy applications rose by 50%, reflecting the growing role of HLA testing in personalized medicine.
Report Coverage of Human Leukocyte Antigen (HLA) Testing MarketÂ
The Human Leukocyte Antigen (HLA) testing market report provides a comprehensive analysis of market trends, growth drivers, technological advancements, and regional developments. The demand for molecular assay-based HLA testing has increased by 65%, making it the dominant technology. The report highlights a 40% rise in laboratory automation, improving diagnostic efficiency.
Market segmentation insights reveal that hospital-based HLA testing accounts for over 55% of total market usage, while research institutions contribute nearly 30%. The adoption of NGS-based HLA typing has grown by 70%, reducing transplant rejection rates by over 50%.
Regional analysis indicates that North America holds nearly 50% of the global market share, while Europe accounts for approximately 30%. Asia-Pacific is the fastest-growing region, with HLA testing demand increasing by 35% annually. The Middle East & Africa are experiencing market growth of nearly 25%, driven by expanding transplant programs.
The report covers key players, including Thermo Fisher Scientific and QIAGEN N.V., which together control over 55% of the global market. Recent advancements in high-resolution typing have increased test accuracy by nearly 80%, shaping the future of the HLA testing industry.
Human Leukocyte Antigen (HLA) Testing Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 770.5 Million in 2026 |
|
|
Market Size Value By |
USD 1616.32 Million by 2035 |
|
|
Growth Rate |
CAGR of 7.69% from 2026 - 2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation
Download FREE Sample
|
||
Frequently Asked Questions
-
What value is the Human Leukocyte Antigen (HLA) Testing Market expected to touch by 2035?
The global Human Leukocyte Antigen (HLA) Testing Market is expected to reach USD 1616.32 Million by 2035.
-
What CAGR is the Human Leukocyte Antigen (HLA) Testing Market expected to exhibit by 2035?
The Human Leukocyte Antigen (HLA) Testing Market is expected to exhibit a CAGR of 7.69% by 2035.
-
What was the value of the Human Leukocyte Antigen (HLA) Testing Market in 2025?
In 2025, the Human Leukocyte Antigen (HLA) Testing Market value stood at USD 770.5 Million.
Our Clients
Trusted & Certified
